14-7-1　ⓔ文献

  1. Praga M, González E: Acute interstitial nephritis. Kidney Int, 2010; 77: 956–961.

  2. Perazella MA, Markowitch GS: Drug–induced acute interstitial nephritis. Nat Rev Nephrol, 2010; 6: 461–470.

  3. Muriithi AK, Leung N, et al: Biopsy–proven acute interstitial nephritis, 1993–2011: A case series. Am J Kidney Dis, 2014; 64: 558–566.

  4. Praga M, Sevillano A, et al: Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant, 2014; 30: 1472–1479.

  5. Barreto EF, Rule AD: Management of drug–associated acute interstitial nephritis. Kidney360, 2020; 1; 62-64.

  6. Shingarev R, Glezerman IG: Kidney complications of immune checkpoint inhibitors: A review. Am J Kidney Dis, 2019; 74: 529–537.

  7. Seethapathy H, Zhao S, et al: The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol, 2019; 14: 1692–1700.

  8. 厚生労働省：重篤副作用疾患別対応マニュアル 間質性腎炎 (尿細管間質性腎炎) 平成30年6月改定．http://www.pmda.go.jp/files/000224770.pdf

  9. Sugiyama S, Yokoyama H, et al: Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol, 2013; 17: 155–173.

  10. Yokoyama H, Narita I, et al: Drug–induced kidney disease: A study of the Japan Renal Biopsy Registry from 2007 to 2015. Clin Exp Nephrol, 2016; 20: 720–730.

  11. Clarkson MR, Giblin L, et al: Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant, 2004; 19: 2778–2783.

  12. Goicoechea M, Rivera Hernandez F, et al: Increased prevalence of acute tubulointerstitial nephritis. Nephrol Dial Transplant, 2013; 28: 112–115.

  13. Valluri A, Hetherington L, et al: Acute tubulointerstitial nephritis in Scotland. Q J Med, 2014; 108: 527–532.

  14. López–Gómez JM, Rivera F, et al: Renal biopsy findings in acute renal failure in the cohort of patients in the Spanish registry of glomerulonephritis. Clin J Am Soc Nephrol, 2008; 3: 674-681.

  15. Ping Z, Fu–de Zhou, et al: The renal histopathology spectrum of elderly patients with kidney diseases: A study of 430 patients in a single Chinese center. Medicine, 2014; 93: e226.

  16. Neilson EG: Mechanism of disease: fibroblasts – a new look at an old problem. Nat Rev Nephrol, 2006; 2: 101–107.

  17. González E, Praga M: Early steroid treatment improves the recovery of renal function in patients with drug–induced acute interstitial nephritis. Kidney Int, 2008; 73: 940-946.

  18. Raza MN, Hadid M, et al: Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes. Nephrology (Carlton), 2012; 17: 748–753.

  19. Prendecki M, Tanna A, et al: Long–term outcome in biopsy–proven acute interstitial nephritis treated with steroids. Clin Kidney J, 2017; 10: 233–239.

  20. Fernandez-Juarez G, Perez JV, et al: Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol, 2018; 13: 1851–1858.

  21. Moledina DG, Perazella MA: Treatment of drug–induced acute tubulointerstitial nephritis. The search for better evidence. Clin J Am Soc Nephrol, 2018; 13: 1785–1787.

  22. Perazella M, Bomback AS: Urinary eosinophils in AIN: Farewell to an old biomarker? Clin J Am Soc Nephrol, 2013; 8: 1841–1833.

  23. 成田一衛，山縣邦弘，他：薬剤性腎障害の診療ガイドライン2016. 日本腎臓学会誌，2016; 58: 477–555.

  24. Wu Y, Yang L, et al. Pathological significance of a panel of urinary biomarkers in patients with drug–induced tubuloineterstitial nephritis. Clin J Am Soc Nephrol, 2010; 5: 1954–1959.

  25. Moledina DG, Wilson FP, et al: Urine TNF–αa and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight, 2019; 4: e127456.

  26. Kshirsagar AV, Falk RJ: Treatment of acute interstitial nephritis. UpToDate (Last updated: May 13, 2019).